NILEMDO® (bempedoic acid) is a new, first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering treatment that significantly reduces LDL-C on top of statins and other lipid-lowering therapies1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in […]